Spots Global Cancer Trial Database for Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

Official Title: Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

Study ID: NCT00804128

Conditions

Breast Cancer

Interventions

Magnetic Resonance Imaging (MRI)

Gadavist

Study Description

Brief Summary: \*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY\* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ. PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and atypical ductal hyperplasia, a risk factor for developing cancer.

Detailed Description: OBJECTIVES: * Compare the DCIS optimized MRI to the standard clinical MRI. Using a scale of 1-5 from poor to excellent, images will be assessed for conspicuity of DCIS and atypical ductal hyperplasia (ADH) lesions, agreement of disease extent with biopsy, and overall image quality (artifact level, uniformity of fat suppression, contrast to noise ratio and signal to noise ratio). * Subjects with ADH, a benign condition that can also show enhancement on MRI, will be enrolled to explore the utility of the DCIS optimized MRI for distinguishing DCIS and ADH.